Explore the vast range of titles available.

Objective: The aim of this study is to determine narrowband UVB (NB-UVB) irradiation’s effect on the promotion of skin cancer, particularly its effect on DNA damage, oxidative stress, inflammation, and histological changes in Wistar rat skin. Materials and Methods: Wistar rats were selected for this study and randomly divided into control, dimethylbenzanthracene (DMBA), and DMBA+NB-UVB groups. The rats were given a single dose of DMBA and exposed to NB-UVB 3 times a week for 10 weeks. The radiation dose started with 1 minimal erythema dose, which is equivalent to 3.192 J/cm². In the 11th week, analysis on cyclobutene pyrimidine dimer (CPD), malondialdehyde (MDA), nuclear factor kappa-B (NFκB), inflammatory cytokines, and histopathology examination of the skin tissue was conducted. Results: Higher CPD, MDA, NFκB, tumor necrosis factor a (TNF-a), interleukin (IL)-6, IL-11, IL-10, and IL-12 levels in rats exposed to DMBA+NB-UVB for 10 weeks compared to control and DMBA groups. Macroscopic examination presented erythema, skin thickening, desquamation, ulcer, and crust. Histopathology examination showed hyperkeratosis, acanthosis, atypical keratinocytes,irregular arrangement of the basement membrane, and inflammatory cell infiltration in the DMBA+NB-UVB group. Conclusion: This research has shown that 10 weeks of a combination of DMBA and NB-UVB irradiation induced DNA damage, oxidative stress, inflammation, and histological changes in the Wistar rat skin.

Dear Editor, Pityriasis lichenoides (PL) is an inflammatory skin disease of unknown etiology. The clinical spectrum of pityriasis lichenoides encompasses febrile ulcer-necrotic Mucha-Habermann disease (FUMHD), pityriasis lichenoides et varioliformis acuta (PLEVA), and pityriasis lichenoides chronica (PLC). Phototherapy is an effective and well-tolerated modality that is often successful for persistent PL or resistant to topical treatments. A retrospective observational study was conducted involving patients from the dermatology section of the University of Verona with a confirmed histological diagnosis of PLEVA and PLC accessed between January 2003 and June 2024. [...]

Hailey-Hailey disease (HHD) is a chronic familial bullous disease characterized by recurrent blisters and erosions typically at friction-prone areas of the body accompanied by acantholysis upon histologic examination. There are a number of therapies used in the management of HHD. Its symptoms have been effectively treated with antimicrobial therapies, corticosteroids and other agents such as cyclosporine and prednisone. However, such treatments are not always effective. Therefore, there is a need for new treatments for the management of HHD. In this report, a patient with long-standing HHD responsive only to high levels of prednisone is described. After the successful tapering and cessation of oral prednisone the patient began a new combination therapy of complementary doses of oral alitretinoin, and narrowband UVB therapy, which yielded a favorable response within 2-3 weeks. After 6 weeks, a mono-therapy of daily (30 mg) oral alitretinoin was sufficient to maintain successful near-complete remission of the disease.

Dear Editor, Pityriasis lichenoides (PL) is an inflammatory skin disease of unknown etiology. The clinical spectrum of pityriasis lichenoides encompasses febrile ulcer-necrotic Mucha-Habermann disease (FUMHD), pityriasis lichenoides et varioliformis acuta (PLEVA), and pityriasis lichenoides chronica (PLC). Phototherapy is an effective and well-tolerated modality that is often successful for persistent PL or resistant to topical treatments. [...]

[LANGUAGE=”English”]Recently, dupilumab treatment in atopic dermatitis (AD) has been an effective and safe option in terms of adverse effects. However, combination therapies can sometimes be better at increasing efficacy or reducing adverse effects or cumulative doses. Early combination therapies may be more rational, especially considering that dupilumab treatment alone is less effective and has a late-onset efficacy. Here, we discussed dupilumab and a short-term narrowband ultraviolet B combination therapy in a child with AD.[LANGUAGE=”Turkish”]Son yıllarda atopik dermatitte (AD) dupilumab tedavisi, oldukça etkin ve yan etkileri açısından oldukça güvenli bir seçenek sunmaktadır. Yine de bu kronik hastalıkta bazen kombinasyon tedavileri ile etkinlik artırılması ya da yan etkiler ve kümülatif dozun azaltılmasına ihtiyaç olabilir. Özellikle dupilumabın likenifiye lezyonlarda etkinliğinin daha az ve geç başladığı göz önüne alındığında erken dönemdeki kombinasyon tedavileri daha akılcı olabilir. Burada, dupilumab başladığımız bir AD’li çocukta, kısa süreli dar bant ultraviyole B kombinasyon tedavisini tartıştık.

Background: The details of phototherapy practices for vitiligo have been rarely studied. Objective: To explore the details of phototherapy practices for vitiligo among dermatologists. Methods: A self-administered questionnaire about the details of phototherapy practices for vitiligo was distributed to all dermatologists attending a national general dermatology conference in Riyadh, Saudi Arabia, in 2008. Results: Questionnaires were returned by 121 of 140 participants (response rate = 86.4%). The mean age of the respondents was 39.34 ± 9.7 years, and 65% were males. One hundred eight of 110 (98.2%) respondents provided phototherapy to their vitiligo patients. The mean number of vitiligo patients who underwent phototherapy each week per dermatologist's office was 18 ± 2.26. Narrowband ultraviolet B (NB-UVB) was the most common modality chosen to treat generalized vitiligo (84%). Excimer laser was the most common modality used to treat focal and segmental vitiligo (53% and 39%, respectively). Sixty-eight percent of dermatologists administered a fixed starting dose of NB-UVB to all patients, whereas 31% used the minimal erythema dose as a guide. Fifty percent reported that NB-UVB resulted in better color matching with the surrounding skin. Thirty-seven percent favored NB-UVB over psoralen + ultraviolet A for a faster response, and 31% preferred NB-UVB for a pigmentation that is more durable. Forty-seven percent (50/106) of the respondents limited the number of phototherapy sessions to reduce the risks of skin cancer. However, no respondent reported any skin cancer incidence in phototherapy-treated vitiligo patients. Conclusion: There is a need for phototherapy guidelines for the treatment of vitiligo in patients with skin of color.

Improved repigmentation of generalized vitiligo in skin types IV–VI has been reported in clinical response to combined therapy with apremilast and narrowband (NB)-UVB; however, tissue responses to combined therapy versus NB-UVB monotherapy have not been elucidated. We compared the change from baseline in cellular and molecular markers in vitiligo skin after combined therapy versus NB-UVB monotherapy. We assessed lesional and nonlesional skin samples from enrolled subjects and evaluated for immune infiltrates, inflammatory, and melanogenesis-related markers which were compared across different treatment groups. Combined therapy resulted in significant reduction of CD8 + T cells and CD11c + dendritic cells, downregulation of PDE4B and Th17-related markers, and upregulation of melanogenesis markers. This study was limited to small sample size, skin types IV–VI, and high dropout rate. Our molecular findings support the clinical analysis that apremilast may potentiate NB-UVB in repigmentation of generalized vitiligo in skin types IV–VI.

Background The natural history of multiple sclerosis (MS) typically presents with the clinically isolated syndrome (CIS), an episode of neurological symptoms caused by central nervous system inflammation or demyelination that does not fulfil the diagnostic criteria for MS. Objective As preclinical studies have suggested that exposure to ultraviolet radiation (UVR) could regulate the development of MS, the Phototherapy for CIS (PhoCIS trial) was established to examine the effects of narrowband UVB phototherapy on patients with CIS, and their conversion to MS. Methods Of the 20 participants, half received 24 sessions of narrowband UVB exposure over eight weeks; participants in both arms were followed for 12 months. All participants were supplemented to 25-hydroxyvitamin D3 levels of >80 nmol/l. Results By 12 months, 100% of those in the no phototherapy arm and 70% in the phototherapy arm had converted to MS, although this difference was not statistically significant. Conclusion This study provides a basis for further studies to determine if there are any benefits of the therapeutic effects of narrowband UVB radiation on MS progression.